Ask AI
ProCE Banner Activity

Experts Discuss Contemporary Treatment of Multiple Myeloma

Clinical Thought

In this commentary, expert faculty respond to healthcare professional questions from a live webinar and share their perspectives on optimal treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Released: March 05, 2025

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner
ProCE Banner

Supporters

This educational activity is supported by an independent medical education grant from GSK and an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

Jens Hillengass, MD, PhD

Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Jens Hillengass, MD, PhD: consultant/advisor/speaker: Janssen, Pfizer, Regeneron, Sebia, The Binding Site.

Carol Ann Huff, MD

Professor of Oncology and Medicine
Multiple Myeloma Program
Johns Hopkins University
Medical Director
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Carol Ann Huff, MD: consultant/advisor/speaker: Bristol Myers Squibb, Janssen, Legend, Prothena, Sanofi Aventis; researcher: Prothena.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant: AbbVie, Amgen, ArcellX, BD Biosciences, BeiGene, Bristol Myers Squibb, CVS Caremark, Carsgen, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda; clinical trial support (paid to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, GSK, Gracell Bio, Janssen, Oricell, Roche/Genentech, Sanofi, Takeda, TeloGenomics.